In the present study, we analyzed 25,315 patients with DM who had started taking SGLT2 inhibitors and demonstrated that there was no significant difference in the risk of developing HF, MI, AP, stroke, and AF among patients taking empagliflozin, dapagliflozin, canagliflozin, and other SGLT2 inhibitors. Here, SLC5A2 is linked to atrial fibrillation.